This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. But it is subject to change as our understanding of the facts evolves.
NewAmsterdam Pharma develops obicetrapib, a novel low-dose oral CETP inhibitor for cardiovascular disease and dyslipidemia. The drug demonstrated statistically significant LDL-lowering across seven clinical trials (Phase 2 ROSE, ROSE2, TULIP, OCEAN and Phase 3 BROOKLYN, BROADWAY, TANDEM) with a side-effect profile similar to placebo. The company enrolled over 9,500 patients in the Phase 3 PREVAIL cardiovascular outcomes trial and is preparing for a potential European commercial launch contingent on an EMA approval decision expected in the second half of 2026. Obicetrapib also showed a 20.5% reduction in Alzheimer's disease biomarker p-tau217 in high-risk ApoE4/E4 carriers. All preclinical development of obicetrapib required FDA-mandated animal pharmacology and toxicology studies, including rodent and non-human primate models to establish cardiovascular safety and lipid-modifying efficacy before human dosing.
Research Sources
1 organization
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.